Live website intelligence
Home - ALIGOS Therapeutics
We discover targeted antiviral therapies for chronic hepatitis B (CHB), COVID-19, and optimized therapeutics for Nonalcoholic Steatohepatitis (NASH).
Last refresh
Updated 27d ago
Analyst read
Professional
Detected stack
Quick read
aligos.com looks like health & medical. Traffic estimates are limited, so use the trust and structure modules first. Current AI trust scoring is 5/100.
What to do next
36/56 fields populated (64%)
Providers with missing fields
visual: 4/4
All expected fields present
meta: 3/3
All expected fields present
seo: 5/5
All expected fields present
dns: 4/4
All expected fields present
ads: 3/5
Missing: advertiserIds, advertiserNames
publisher: 2/5
Missing: adSystems, directCount, resellerCount
files: 2/3
Missing: robotsSitemapUrls
traffic: 0/10
Missing: monthlyVisits, globalRank, countryRank, bounceRate, avgVisitDuration, pagesPerVisit, topCountry, topRegions, topKeywords, trafficSources
whois: 6/6
All expected fields present
radar: 0/4
Missing: globalRank, rankBucket, categories, sourceTimestamp
ai: 7/7
All expected fields present
Keep exploring
Good pSEO pages should not strand the visitor. These links keep the journey moving through adjacent directories and comparable live reports.
Why this module matters
Use the business tab to understand trust, monetization, audience fit, and brand posture before you spend time on outreach, partnerships, or competitive teardown work.
Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted antiviral therapies for chronic hepatitis B (CHB), COVID-19, and treatments for Nonalcoholic Steatohepatitis (NASH).
Monetization Signals
Biotech/Pharmaceutical R&D model detected
Low trust with 5/100 score
Patients with chronic hepatitis B, NASH, and viral diseases; healthcare providers; investors; and potential research partners